|
Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study. |
|
|
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals |
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics |
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst) |
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer (Inst) |
Research Funding - Bayer (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); Hutchison MediPharma (Inst); Merck (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Treos Bio (Inst) |
|
|
Stock and Other Ownership Interests - CytoDyn; Oncotherapeutics |
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genentech/Roche; Ipsen; Merrimack; Vicus Therapeutics |
Research Funding - Agios; ARIAD; ArQule; AstraZeneca (Inst); Basilea (Inst); FibroGen; Gritstone Bio (Inst); Incyte (Inst); MedImmune; Merck (Inst); Senhwa Biosciences; Taiho Pharmaceutical; TRACON Pharma; Turnstone Bio (Inst); Vyriad (Inst) |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Daiichi Sankyo; Eisai; Ipsen; MSD Oncology; Novartis |
Speakers' Bureau - Ipsen; Lilly |
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Cellid; Eisai; Immunome; medpacto; MSD Oncology; Roche/Genentech; Sillajen |
|
|
Consulting or Advisory Role - Ipsen; Seattle Genetics/Astellas; Taiho Pharmaceutical |
|
|
Honoraria - Bristol-Myers Squibb; Incyte; OncLive |
Speakers' Bureau - Allergan (I); Teva (I) |
Research Funding - AstraZeneca (Inst); Boston Scientific (I); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Merck (Inst); OncoMed (Inst); Roche (Inst); Senhwa Biosciences (Inst) |
|
|
Employment - Senhwa Biosciences |
Leadership - Senhwa Biosciences; Senhwa Biosciences |
Stock and Other Ownership Interests - Senhwa Biosciences |
Patents, Royalties, Other Intellectual Property - I hold multiple patents relating to the small molecules CX-4945 and CX-5461 |
Travel, Accommodations, Expenses - Senhwa Biosciences |
|
|
Employment - Senhwa Biosciences |
Stock and Other Ownership Interests - Senhwa Biosciences |
|
|
Employment - Senhwa Biosciences |
Stock and Other Ownership Interests - Pfizer |
|
|
Consulting or Advisory Role - Celltrion (I); Eisai; Exelixis; Genentech/Roche |
Research Funding - AstraZeneca; Bayer |
|
|
Research Funding - Astellas Pharma (Inst); Halozyme (Inst); Pharmacyclics (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks |
Research Funding - Array BioPharma; AstraZeneca; Lilly; Novartis |
|
|
Consulting or Advisory Role - AstraZeneca; Celgene; GI Innovation; Merck Serono; SERVIER |
Speakers' Bureau - Celgene |
Research Funding - Celgene; medpacto |
|
|
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb-Ono Pharmaceutical; Eisai; Ipsen; Lilly; Merck Serono; MSD; Novartis; PharmaEngine; Roche; TTY Biopharm |
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical; Ipsen; Roche |
Travel, Accommodations, Expenses - Ipsen; PharmaEngine; Roche; TTY Biopharm |
|
|
Honoraria - Taiho Pharmaceutical |
Consulting or Advisory Role - Agenus; Bayer; HERON; Ipsen; SOBI; Takeda |
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Taiho Pharmaceutical |
|
|
Research Funding - Astellas Pharma; AstraZeneca; Debiopharm Group; Janssen; Lilly; Merck KGaA; MSD Oncology; Ono Pharmaceutical; Roche; Senhwa Biosciences; SynCoreBio; TTY Biopharm |
|
|
No Relationships to Disclose |